–
Статьи в журналах
-
- 2024 CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG CANCER WITH PD-L1 ≥ 1 %: A SUBGROUP ANALYSIS FROM THE EMPOWER-LUNG 3 PART 2 TRIAL
- BARAMIDZE A., MAKHARADZE T., GOGISHVILI M., MELKADZE T., GIORGADZE D., PENKOV K., LAKTIONOV K., NEMSADZE G., NECHAEVA M., ROZHKOVA I., KALINKA AG E.MCINTYRE D, PEREZ JA, KAUL M., QUEK R.G.W, SEEBACH F., RIETSCHEL P.T., POULIOT J.F.J.F
- в журнале Lung Cancer, издательство Elsevier BV (Netherlands), том 193 DOI
-
- 2023 Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
- Makharadze T., Gogishvili M., Melkadze T., Baramidze A., Giorgadze D., Penkov K., Laktionov K., Nemsadze G., Nechaeva M., Rozhkova I., Kalinka E., Li S, Li Y, Kaul M., Quek RGW, Pouliot JF, Seebach F., Lowy I., Gullo G., Rietschel P.
- в журнале Journal of Thoracic Oncology, издательство Lippincott Williams & Wilkins Ltd. (United States), том 18, № 6, с. 755-768 DOI